Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RNAZ with free AI briefings, catalyst countdowns, and dilution alerts.

RNAZ · Transcode Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$8.4M Cash on Hand
4.8mo Cash Runway
Follow RNAZ by email Get an email when RNAZ reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RNAZ, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Evorpacept (ALX148) HER2-positive Breast Cancer Phase 1/2 · NCT05868226 Recruiting
MicroRNA-10b Antagomir-Iron Oxide/Dextran-based… Advanced Solid Tumor Phase 1/2 · NCT06260774 Active not recruiting
Copper Cu 64 NODAGA-TTX-MC138 Advanced Solid Tumor Early Phase 1 · NCT05908773 Completed

Also used in these trials (approved or third-party drugs, not RNAZ's own candidates): Fam-Trastuzumab Deruxtecan-Nxki, Tucatinib, Zanidatamab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RNAZ holds $8.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $5.2M/quarter from operations, an estimated runway of 4.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 65 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RNAZ files for a raise →

👥 Who Owns RNAZ

Insiders 81.7% Other 5%+ holders 4.5% Institutions 0.5% Public and other holders 13.3%
HolderTypeShares% of sharesAs of
DEFJ, LLC
10% owner
Insider 14,134,481 81.68% 2026-08-03
Unleash Immuno Oncolytics, Inc. 5%+ holder (13G) 300,000 1.73% 2026-07-23
Elena Rosa Braci 5%+ holder (13G) 186,236 1.08% 2026-07-23
Daniel Eduardo Katzman 5%+ holder (13G) 155,611 0.90% 2026-07-23
YA II PN, Ltd. 5%+ holder (13G) 101,772 0.59% 2026-04-15
CK Life Sciences Int'l., (Holdings) Inc. Institution (13G, 5%+) 83,285 0.48% 2025-10-27
Thomas Joseph Tracy 5%+ holder (13D) 35,000 0.20% 2025-03-07

Share count 17,303,883 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full RNAZ picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RNAZ and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.